What happened with TELA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
TELA Bio supplies OviTex implants for hernia repair and abdominal wall reconstruction, and OviTex PRS implants for plastic and reconstructive surgery. These products combine tissue material derived from sheep stomachs with interwoven polymer fibers for reinforcement. Hospitals and ambulatory surgery centers buy them principally through the company’s direct sales team. U.S. sales of these two product lines generate nearly all revenue, with OviTex contributing the majority.
TELA Bio depends on Aroa, its exclusive manufacturer and supplier, which makes both product lines in Auckland, New Zealand. TELA Bio pays Aroa a share of product sales under their supply and licensing agreement, with a minimum transfer-cost payment for certain hernia products. This arrangement makes Aroa central to both product availability and the economics of each sale.
Sales depend on surgeons choosing the products and on hospitals’ ability to obtain reimbursement for the procedures. Regulatory authorization also limits their use: neither OviTex nor OviTex PRS is cleared or approved for breast surgery, so TELA Bio cannot market them for that purpose without specific approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
TELA Bio’s results hinge on hospitals adopting its tissue matrices and on reliable supply from Aroa, the exclusive manufacturer of OviTex and OviTex PRS.
Becton, Dickinson’s Bard competes for hospitals’ hernia-repair and reconstructive-surgery purchases with TELA Bio’s tissue matrices. Watch Bard’s Phasix and Ventralight ST for hernia repair and GalaFLEX for reconstruction, rather than BD’s broader medical-device results.
Integra LifeSciences competes with TELA Bio for purchases of materials used in plastic and reconstructive surgery: its SurgiMend and DuraSorb compete with OviTex PRS. News about those products is more relevant to TELA Bio than Integra’s larger neurosurgery business.
AbbVie’s Allergan competes for purchases of hernia-repair and reconstruction materials with TELA Bio: Strattice competes with OviTex, and AlloDerm with OviTex PRS. Those products are the ones to watch for pressure on TELA Bio, not AbbVie’s overall medicines sales.
Becton, Dickinson and Co. earningsBDX
If Becton Dickinson reports demand for Bard hernia-repair products, its results will show how hospitals are buying in a market where TELA Bio’s OviTex competes.
Look for specific discussion of demand for Bard’s Phasix and Ventralight ST hernia-repair products; if Becton Dickinson does not report on them separately, its overall results cannot establish how those products sold. Strong demand would show hospitals continue to buy established alternatives, leaving TELA Bio’s OviTex competing for hospital purchases and procedures. Weak demand would soften that competitive signal, but would not show that hospitals switched to OviTex.
TELA Bio, Inc. earningsThis company
TELA Bio’s report will show whether sales growth from OviTex and OviTex PRS is keeping pace with the pressure that lower hernia-product prices put on gross profit.
Read revenue growth alongside gross margin. Faster growth with a steady or rising margin would mean revenue from new customers and product mix is offsetting the lower prices associated with a greater share of smaller hernia products. Slower growth and a falling margin would mean sales expansion is translating less well into gross profit. Net loss shows the cost of continuing to build the business. Together, these figures show whether TELA Bio’s growth is producing stronger product economics or still depends on substantial investment.
